Oppenheimer analyst Jay Olson lowered the firm’s price target on Enanta (ENTA) to $14 from $16 and keeps an Outperform rating on the shares. The firm notes the company reported Q4 results with quarterly HCV royalties of $14.6M, OpEx of $44.5M, and $248.2M cash expected to provide runway into 2027. Enanta remains on track to report topline results from Phase 2 RSVPEDs study of zelicapavir in infants and children with RSV in December.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENTA:
- Enanta price target lowered to $20 from $26 at Baird
- Enanta price target lowered to $21 from $22 at JMP Securities
- Enanta Pharmaceuticals Reports Q4 2024 Financials
- Closing Bell Movers: Semtech rises, Zoom falls after earnings
- Enanta reports Q4 EPS ($1.36), consensus (92c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
